Three Cancer Center Leaders To Serve on AACI Board

AACI congratulates Gerold Bepler, MD, PhD, C. Kent Osborne, MD, and Timothy L. Ratliff, PhD on their selection to serve on AACI’s Board of Directors. Their terms will start on October 15, during the AACI/CCAF annual meeting, in Washington, DC.

Dr. Bepler, President and Chief Executive Officer, Barbara Ann Karmanos Cancer Institute, in Detroit, and Dr. Ratliff, director of the Purdue University Center for Cancer Research, in West Lafayette, Indiana, were elected to three-year terms. Dr. Osborne, director of the Dan L Duncan Cancer Comprehensive Center, Baylor College of Medicine, in Houston, was appointed to a one-year term.

Dr. Bepler has spent his career researching risk, biology, treatment, and outcomes related to lung cancer, with a focus on non-small cell lung cancer. His research experience spans the full spectrum from bench to clinical and population research, and he has conducted and published work in cell biology, molecular genetics, clinical and translational sciences, early detection, and risk intervention. More than 20 years ago, his research findings drove his passion for and involvement in the development of personalized medicine.

Dr. Ratliff is recognized for his achievements in urologic research. He was a member of the team that validated the PSA (prostate- specific antigen) screening test that is widely used to detect prostate cancer and was a leader in the launch of intravesical BCG therapy for non-muscle invasive bladder cancer, currently the treatment of choice for the disease. Dr. Ratliff founded and launched the Society for Basic Urologic Research and is a member of several other scientific societies.

Dr. Osborne is a physician scientist who has focused on breast cancer his entire career. His research interests include understanding the biology of breast cancer and then developing new treatment approaches for the disease. He has published extensively on the mechanisms by which hormonal therapies such as tamoxifen inhibit breast cancer growth and how breast cancers become resistant to these therapies. He has also studied the role of various growth factors in breast cancer development and progression, and more recently how these other growth factors can interact with estrogen to stimulate tumor growth. His laboratory is also focusing on the mechanisms by which breast cancers develop resistance to HER2-targeted therapies.